Injections of semaglutide and other GLP-1 receptor agonists significantly reduce the frequency of asthma exacerbations in people with obesity and type 2 diabetes, reports infohub.kz.
Popular weight-loss and diabetes drugs, including semaglutide and liraglutide, can cut asthma attacks by up to 40%. Researchers presented these findings at the European Respiratory Society Congress. The team analyzed clinical data from patients with both asthma and metabolic disorders.
GLP-1 receptor agonists showed high effectiveness in reducing the severity of respiratory symptoms. Within a year of starting therapy, the rate of acute exacerbations dropped by 26–40% compared to the previous period. Additionally, the need for rescue inhalers decreased by 14%, and daily use of inhaled corticosteroids fell by 23%. The researchers also observed a reduced risk of pneumonia.
The specialists attribute these results not only to overall weight loss but also to a direct effect of the drugs on lung tissue, where GLP-1 receptors are present. Excess fat tissue causes systemic inflammation that worsens asthma, and these new drugs help eliminate that factor. The authors emphasize that further clinical trials will help determine the exact therapeutic mechanisms and confirm the benefits of these injections for preventing attacks in a broader patient population.
Important information: This material is for informational purposes only and is not a guide to action. Drugs based on semaglutide and other GLP-1 receptor agonists are serious prescription medications with a wide range of contraindications and side effects. Using these drugs without a doctor's prescription can seriously harm your health. Before starting any treatment or taking medication, be sure to consult a qualified physician.